References
- PeruccaETomsonTThe pharmacological treatment of epilepsy in adultsLancet Neurol201110544645621511198
- KwanPBrodieMJEarly identification of refractory epilepsyN Engl J Med2000342531431910660394
- BrodieMJBarrySJBamagousGAPatterns of treatment response in newly diagnosed epilepsyNeurol2012782015481554
- PeruccaPGilliamFGAdverse effects of antiepileptic drugsLancet Neurol201211979280222832500
- LoscherWMechanisms of drug resistanceEpileptic Disord20057Suppl 1S3S916120487
- PitkanenALukasiukKMechanisms of epileptogenesis and potential treatment targetsLancet Neurol201110217318621256455
- WhiteHSSmithMDWilcoxKSMechanisms of action of antiepileptic drugsInt Rev Neurobiol2007818511017433919
- StephenLJBrodieMJAntiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adultsCurr Opin Neurol201225216417222322411
- MayerMLArmstrongNStructure and function of glutamate receptor ion channelsAnnu Rev Physiol20046616118114977400
- HwaGGAvoliMThe involvement of excitatory amino acids in neocortical epileptogenesis: NMDA and non-NMDA receptorsExp Brain Res19918622482561684548
- LeeWLHablitzJJInvolvement of non-NMDA receptors in picrotoxin-induced epileptiform activity in the hippocampusNeurosci Lett19891071–31291342575723
- PerreaultPAvoliMPhysiology and pharmacology of epileptiform activity induced by 4-aminopyridine in rat hippocampal slicesJ Neurophysiol19916547717851675671
- BarnaBSzaszAVilagiIAnticonvulsive effect of AMPA receptor antagonist GYKI 52466 on 4-aminopyridine-induced cortical ictal activity in ratBrain Res Bull200051324124810718516
- NeumanRCherubiniEBen-AriYEpileptiform bursts elicited in CA3 hippocampal neurons by a variety of convulsants are not blocked by N-methyl-D-aspartate antagonistsBrain Res198845922652742902900
- HwaGGAvoliMExcitatory synaptic transmission mediated by NMDA and non-NMDA receptors in the superficial/middle layers of the epileptogenic human neocortex maintained in vitroNeurosci Lett19921431–283861359479
- RogawskiMARevisiting AMPA receptors as an antiepileptic drug targetEpilepsy Curr2011112566321686307
- ChappellASSanderJWBrodieMJA crossover, add-on trial of talampanel in patients with refractory partial seizuresNeurol2002581116801682
- LanganYMLucasRJewellHTalampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsyEpilepsia2003441465312581229
- HanadaTHashizumeYTokuharaNPerampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsyEpilepsia20115271331134021635236
- CeolinLBortolottoZABannisterNA novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampusNeurochem Int201261451752222433907
- BalannikVMennitiFSPaternainAVMolecular mechanism of AMPA receptor noncompetitive antagonismNeuron200548227928816242408
- TempletonDFerryJPharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonistEpilepsia2009509899
- Fycompa [perampanel] [webpage on the Internet]European Medicines Agency2012 [updated November 27, 2012]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002434/human_med_001572.jsp&mid=WC0b01ac058001d124Accessed March 1, 2013
- MarsonAGWilliamsonPRInterpreting regulatory trials in epilepsyCurr Opin Neurol200922216717319532041
- KraussGLBarMBitonVTolerability and safety of perampanel: two randomized dose-escalation studiesActa Neurol Scand2012125181521883097
- FrenchJAKraussGLSteinhoffBJEvaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305Epilepsia201354111712522905857
- FrenchJAKraussGLBitonVAdjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304Neurol2012796589596
- KraussGLSerratosaJMVillanuevaVRandomized phase III study 306: adjunctive perampanel for refractory partial-onset seizuresNeurol2012781814081415
- KraussGLPeruccaEBen-MenachemEPerampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307Epilepsia201354112613422905878
- RektorIKraussGLBarMPerampanel Study 207: long-term open-label evaluation in patients with epilepsyActa Neurol Scand2012126426326922913800
- RheimsSPeruccaECucheratMFactors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysisEpilepsia201152221923321269281
- GazzolaDMBalcerLJFrenchJASeizure-free outcome in randomized add-on trials of the new antiepileptic drugsEpilepsia20074871303130717521343
- RheimsSCucheratMArzimanoglouAGreater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsyPLoS Med200858e16618700812
- CallaghanBCAnandKHesdorfferDLikelihood of seizure remission in an adult population with refractory epilepsyAnn Neurol200762438238917880009
- RyvlinPCucheratMRheimsSRisk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trialsLancet Neurol2011101196196821937278